Renal cell carcinoma: focus on safety and efficacy of temsirolimus.
about
Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trialmicroRNA-210-3p depletion by CRISPR/Cas9 promoted tumorigenesis through revival of TWIST1 in renal cell carcinoma.miR-125b is associated with renal cell carcinoma cell migration, invasion and apoptosis.Tumor suppressive microRNA‑138 contributes to cell migration and invasion through its targeting of vimentin in renal cell carcinoma.microRNA-451 inhibited cell proliferation, migration and invasion through regulation of MIF in renal cell carcinomaCRM1 inhibitor S109 suppresses cell proliferation and induces cell cycle arrest in renal cancer cells.MicroRNA-27a functions as a tumor suppressor in renal cell carcinoma by targeting epidermal growth factor receptor.β-Catenin promotes cell proliferation, migration, and invasion but induces apoptosis in renal cell carcinoma.Temsirolimus: a safety and efficacy review.Incidence and risk of rash to mTOR inhibitors in cancer patients--a meta-analysis of randomized controlled trials.Targeted therapies for treatment of renal cell carcinoma: recent advances and future perspectives.Tumour-suppressive microRNA-29s directly regulate LOXL2 expression and inhibit cancer cell migration and invasion in renal cell carcinoma.The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinoma.CRISPR-Cas9: a promising genetic engineering approach in cancer research.miR-216a-5p acts as an oncogene in renal cell carcinoma.
P2860
Q33410691-7675574A-14CB-4BAC-BFCF-5222E5F46B3EQ33591384-89BFCF38-7383-4EAF-A33F-0D96DB358606Q33751241-42FA51C2-4C4E-4482-BAE8-508200E4F4DEQ34286271-A12D6AF7-1995-43EC-9573-4F29CF320BA5Q36511669-7C0F96EA-012F-4429-BCD8-94C3F21164DEQ36627593-B403ECE1-EF0F-4D40-A929-05966CC66C98Q36954217-8A2ED14E-8480-4BAD-B156-C1BA6F5062BCQ37669551-7CBD6F70-4546-4772-86C4-4FEF6E00467FQ38031941-66D38325-B8A8-4868-8636-270B49992DB0Q38219039-3E3BBE26-6577-4007-89C2-DB38B1658F56Q38473672-C072074B-99F0-4A14-B6F6-F17EC871154DQ38861461-57DCB7BC-A2D4-416C-8D85-9BE5511D8A7BQ39568931-0864B8F4-3A75-400C-90B9-B8BABB8CF04DQ49477344-B83DB60B-2F1F-4CF9-BD27-9F4BC4BDB0C6Q54094665-151C7C6F-914A-4DB1-B5C1-15CE4CF40FD7
P2860
Renal cell carcinoma: focus on safety and efficacy of temsirolimus.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 December 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Renal cell carcinoma: focus on safety and efficacy of temsirolimus.
@en
Renal cell carcinoma: focus on safety and efficacy of temsirolimus.
@nl
type
label
Renal cell carcinoma: focus on safety and efficacy of temsirolimus.
@en
Renal cell carcinoma: focus on safety and efficacy of temsirolimus.
@nl
prefLabel
Renal cell carcinoma: focus on safety and efficacy of temsirolimus.
@en
Renal cell carcinoma: focus on safety and efficacy of temsirolimus.
@nl
P2093
P2860
P356
P1476
Renal cell carcinoma: focus on safety and efficacy of temsirolimus.
@en
P2093
Julien Hadoux
Stephane Vignot
Thibault De La Motte Rouge
P2860
P304
P356
10.4137/CMO.S4482
P407
P577
2010-12-19T00:00:00Z